Evaluation of factors associated with survival in dogs with untreated nasal carcinomas: 139 cases (1993–2003)

Rassnick, Kenneth M.; Goldkamp, Carrie E; Erb, Hollis N.; Scrivani, Peter V.; Njaa, Bradley L.; Gieger, Tracy L.; Turek, Michelle; McNiel, Elizabeth A.; Proulx, David; Chun, Ruthanne; Mauldin, Glenna E.; Phillips, Brenda; Kristal, Orna

doi:10.2460/javma.229.3.401

Cited by 74 publications

(105 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overexpression of COX-2 has been demonstrated in various canine neoplasms. Rassnick et al [9] and Borzacchiello et al [10] provided evidence of similar overexpression in canine nasal carcinomas. Recent studies in rodents, dogs, and humans indicated that COX-2 inhibitors may have chemopreventive and antitumor activity [10].…”

Section: Discussionmentioning

confidence: 87%

“…Nasal carcinoma is uncommon in dogs and treatment is both difficult and controversial. The median survival time is 3.1 months, and the probability of surviving up to 1 and 2 years after diagnosis was only 12% and 2%, respectively [9]. Vanherberghen et al [2] considered epistaxis as a poor prognosis; once the dogs had epistaxis at the time of diagnosis, the survival time was 88 days.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cyclooxygenase Inhibitor Associated with Carboplatin in Treatment of Metastatic Nasal Carcinoma in Dog

Fonseca-Alves

Corrêa

Elias³

et al. 2014

Case Reports in Veterinary Medicine

View full text Add to dashboard Cite

A 10-year-old, intact male, pinscher was presented with unilateral bloodstained nasal discharge, sneezing, dyspnea, zygomatic arch deformity, submandibular lymph node increase, blindness in right eye, and exophthalmia. After clinical examination, it was found that the animal presented with upper respiratory tract dyspnea origin, possibly caused by an obstructive process. Complete blood count (CBC), ocular ultrasonography, thoracic radiographs, mandibular lymph node, and nasal sinus fine needle aspiration were performed. The right mandibular lymph node excisional biopsy was conducted and a tumor sample was obtained through the nasal fistula at hard palate. The material was processed, paraffin embedded, sectioned, and stained with hematoxylin and eosin. Immunohistochemical staining for cytokeratin (AE1/AE3), vimentin, and COX-2 was performed. After histopathological evaluation nasal carcinoma diagnosis was obtained. Chemotherapy was established with carboplatin 300 mg/m 2 intravenouslyfour cycles with intervals of 21 days-and firocoxib 5 mg/kg orally every 24 hours for 7 months. After 7 months the treatment started, the animal presented with ataxia, vocalization, hyperesthesia, and anorexia. Due the clinical condition presented, the animal owner opted for performing euthanasia. The chemotherapy protocol was effective causing the disease stagnation, minimizing the clinical signs, and extending patient survival and quality of life.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Cyclooxygenase Inhibitor Associated with Carboplatin in Treatment of Metastatic Nasal Carcinoma in Dog

Fonseca-Alves

Corrêa

Elias³

et al. 2014

Case Reports in Veterinary Medicine

View full text Add to dashboard Cite

show abstract

“…The prognosis of dogs with untreated nasal carcinoma is poor, and the median survival time is 95 days. However, early control of the clinical signs during the first session of chemotherapy may help to increase the survival time (Rassnick et al 2006). Epistaxis control in canine nasal neoplasia has been associated with longer survival time.…”

Section: Discussionmentioning

confidence: 99%

“…Of all sinonasal tumors, approximately two thirds are of epithelial origin. The most frequent nasal neoplasias are adenocarcinomas, SCCs and TCCs (Saunders et al 2003;, Lana et al 2004;Rassnick et al 2006). Many studies and reports have described TCC in the nasal cavity and its prevalence among nasal neoplasias ranges from 12-50% (Theon et al 1993;Borzacchiello et al 2004;Langova et al 2004;Impellizeri and Esplin 2008;Vanherberghen et al 2009).…”

Section: Discussionmentioning

confidence: 99%

“…The long-term prognosis for dogs with nasal carcinoma is poor. Patients usually die within six months of the diagnosis (Rassnick et al 2006). Studies that have evaluated COX-2 expression in canine nasal tumours have found that 71% to 87% of nasal carcinomas are COX-2-positive (Borzacchiello et al 2004;Kleiter et al 2004;Impellizeri and Esplin 2008), suggesting that COX-2 may participate in nasal tumourigenesis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cox-2 expression after chemotherapy in a canine nasal transitional cell carcinoma: a case report

Ojeda¹,

Moroni²,

Mieres³

et al. 2013

Vet. Med. - Czech

View full text Add to dashboard Cite

An eight year-old mixed breed dog was referred for evaluation with chronic sneezing, epistaxis and nasal bone deformation. A clinical exam revealed a deformity of the left nasal bone. Cytological evaluation of the nasal cavity showed round and cuboid cells in different stages of maturation. Computed tomography images identified a diffuse soft tissue mass in the nasal cavity. The histopathological diagnosis was transitional cell carcinoma. Chemotherapy with cisplatin and piroxicam was initiated. Computed tomography was used to follow the chemotherapy outcome. As many nasal carcinomas express COX-2, its expression was evaluated before and after chemotherapy. Computed tomography revealed a significant reduction of the tumour mass. Inmunohistochemistry showed a marked decrease in COX-2 expression and after 1120 days, the dog remained without clinical signs. Thus, the use of piroxicam and cisplatin is revealed to be effective in the treatment of a nasal transitional carcinoma in a dog. Also, it is possible to postulate that a decrease in COX-2 expression after chemotherapy may be regarded as an indication for a good response to the treatment and favourable outcome. To the authors' knowledge this is the first report that evaluates COX-2 expression after chemotherapy.

show abstract

Respiratory Tract and Thorax

Martano¹,

Boston²,

Morello³

et al. 2012

Veterinary Surgical Oncology

View full text Add to dashboard Cite

Evaluation of factors associated with survival in dogs with untreated nasal carcinomas: 139 cases (1993–2003)

Abstract: The prognosis of dogs with untreated nasal carcinomas is poor. Treatment strategies to improve outcome should be pursued.

Cited by 74 publications

References 23 publications

Cyclooxygenase Inhibitor Associated with Carboplatin in Treatment of Metastatic Nasal Carcinoma in Dog

Cyclooxygenase Inhibitor Associated with Carboplatin in Treatment of Metastatic Nasal Carcinoma in Dog

Cox-2 expression after chemotherapy in a canine nasal transitional cell carcinoma: a case report

Respiratory Tract and Thorax

Contact Info

Product

Resources

About